Press release from Companies

Publicerat: 2022-07-08 09:45:00

SynAct Pharma AB: SynAct Pharma AB publishes prospectus for list change to Nasdaq Stockholm

SynAct Pharma AB ("SynAct" or the "Company") announced on June 28, 2022 that Nasdaq Stockholm’s listing committee has approved that the company’s shares are admitted to trading on Nasdaq Stockholm Main Market. The prospectus that has been prepared in connection with the list change has today been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and is now available on SynAct’s website, www.synactpharma.com, and will be available on the Swedish Financial Supervisory Authority’s website, www.fi.se.

A listing of the Company’s shares on Nasdaq Stockholm is an important step in SynAct’s continued development and gives the Company further access to the Swedish and international capital markets. SynAct has been listed on Spotlight Stock Market since 2016, but the board of directors believes that the listing of the Company’s share on Nasdaq Stockholm will increase the conditions for broadening SynAct’s shareholder base and give the Company access to additional international and institutional investors, which is deemed to promote the Company’s continued development. Furthermore, the listing also carries a quality stamp for SynAct and its operations.

SynAct’s shares will be traded in the Mid Cap segment under the ticker SYNACT and ISIN code SE0008241491. There will be no offering to subscribe for or otherwise acquire new shares in connection with the list change. Shareholders in SynAct do not need to take any actions. The first day of trading on Nasdaq Stockholm Main Market is Tuesday, July 12, 2022 and the last day of trading on Spotlight Stock Market is Monday, July 11, 2022.

Setterwalls Advokatbyrå AB is acting as legal advisor to SynAct in connection with the listing.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

The information was submitted, through the agency of the contact person below, for publication at 09:45 CEST on July 8, 2022.

For further information about SynAct Pharma AB, please contact:  

Jeppe Øvlesen                                    
CEO, SynAct Pharma AB                    
Phone: +45 28 44 75 67                       
Mail: joo@synactpharma.com

Patrik Renblad
CFO, SynAct Pharma AB
Phone: +46 707 47 97 68

Mail: par@synactpharma.com

About SynAct Pharma AB 

SynAct Pharma AB conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms. For more information: www.synactpharma.com. 

Läs mer hos Cision
Läs mer om SynAct Pharma AB